Very simple. Waiting for data confirming that whatever IMU got to offer is the real deal. Before end of 2021 Big Pharma was buying anything that looked great from test tube result to approved drug. That has changed, the focus is now on PH 1b / 2 that could lead to early approval without a PH3. IMU got 2 in that category, CF33 and Azer-Cel. CHM got 2 as well. That's when LC / JC and PH talk about "being on the radar" of Big Pharma. Problem for all IMU like comps is that Big Pharma gets inundated every day with requests to partner some break through therapy. They got the big number of developments spread out in front of them and have to choose. Too many to pick the winner at first sight, they want and need data that meets their criteria to make a decision.
IMU is getting closer, the market getting more and more impatient. Hence the steadily widening gap between progress and the sp. NEU is that great example, the market waiting, ignoring $3-5, happy to pay $20-25. They have been told but wanted reassurance. Same applies to IMU. 8c? No thanks, I wait for $1. As I had often to ask my clients "How expensive do I have to make it for you to be convinced to buy it?" Silly, but that's how it works.
GLTA
IMU Price at posting:
8.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)